Marbofloxacin, like other fluoroquinolones, is used to treat susceptible bacteria in a variety of species. It is approved for use in dogs and cats in the United States and in other species outside the United States. Infections treated with marbofloxacin include skin and soft tissue infections, bone infections, urinary tract infections (UTIs), pneumonia, and infections caused by intracellular organisms. Marbofloxacin has been effective for some blood-borne pathogens such as Mycoplasma haemofelis in cats at a dosage of 2.75 mg/kg q24h PO for 14 days. Marbofloxacin also has been used in horses to treat infections caused by susceptible bacteria. In calves, it has been used to treat respiratory infections (bovine respiratory disease) at 2 mg/kg for 3–5 days or a single dose administered once at 8–10 mg/kg. In sows it is used to treat mastitis–metritis–agalactia (MMA) syndrome. In pigs, doses of 2 mg/kg and higher reached the therapeutic targets for swine respiratory disease pathogens. (See Regulatory Information regarding limitations for use in food animals in the United States.)
